|View printer-friendly version|
"Beta-thalassemia is a rare genetic blood disorder that is characterized by impaired red blood cell production that can result in life-threatening chronic anemia, usually requiring regular and life-long blood transfusions for survival. Over time, these transfusions can lead to excessive iron levels in the body which can be toxic and consequently lead to end-stage damage to vital organs such as the liver and the heart," said
Protagonist recently completed a Phase 1 study of PTG-300 that established pharmacodynamic-based clinical proof-of-concept by achieving dose-related and sustained reductions in serum iron levels in normal healthy volunteers. It was well tolerated with no serious adverse events or dose-limiting toxicities. The company intends to initiate a global clinical trial with PTG-300 in patients with beta-thalassemia following our upcoming meetings with the U.S. and European regulatory agencies.
About PTG-300 and Hepcidin
PTG-300, an injectable hepcidin mimetic, is currently in clinical development for the potential treatment of beta-thalassemia, a rare disease characterized by chronic anemia and iron overload. PTG-300 therapy may also be potentially beneficial in other diseases such as myelodysplastic syndrome (MDS), hereditary hemochromatosis (HH), polycythemia vera (PCV), siderophilic infections, and liver fibrosis which provide additional opportunities for future development. Hepcidin is a natural peptide hormone that is the main regulatory hormone governing iron absorption, recycling and utilization by the body. Iron plays an essential role in various body functions, especially blood formation, but too much iron is toxic and causes organ damage over time. Abnormally low hepcidin levels, caused by genetic mutations or secondary pathology, can result in the body absorbing and storing more iron than is needed, leading to iron overload.
About Orphan Drug Designation
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. Two of its clinical stage product candidates, PTG-100 and PTG-200, are oral targeted therapy drugs being developed for inflammatory bowel diseases (IBD). The alpha-4-beta-7 integrin antagonist peptide PTG-100 is currently in a Phase 2b clinical trial for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist peptide PTG-200 is currently being studied in a Phase 1 clinical trial in healthy volunteers to support further development in Crohn's disease. Both alpha-4-beta-7 integrin and IL-12/23 pathway blockade are approaches that have been validated through
Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland,
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our programs, the initiation and availability of results of our clinical trials and research and development. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses, our reliance on third parties and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to obtain and maintain regulatory approval of our product candidates, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our quarterly report on Form 10-Q filed with the
View original content with multimedia:http://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-for-protagonist-therapeutics-ptg-300-for-the-treatment-of-beta-thalassemia-300609386.html
Joan Kureczka, Bioscribe, Inc., Tel: +1 415-821-2413, Email: Joan@Bioscribe.com; or for Investors: The Trout Group, Marcy Nanus, Tel: +1 646-378-2927, Email: email@example.com